Evolus (EOLS) News Today $11.55 +0.32 (+2.85%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Diadema Partners LP Takes Position in Evolus, Inc. (NASDAQ:EOLS)Diadema Partners LP bought a new position in Evolus, Inc. (NASDAQ:EOLS - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 97,423 shares of the company's stock, valued at approximately $1,076,000. Diadema Partners LP owned 0.15%April 24 at 7:16 AM | marketbeat.comEversept Partners LP Decreases Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)Eversept Partners LP cut its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 15.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 383,045 shares of the company's stock after selling 70April 24 at 7:09 AM | marketbeat.comEvolus: Two-Product Aesthetics Company With A Competitive EdgeApril 22 at 7:10 PM | seekingalpha.comFormula Growth Ltd. Lowers Holdings in Evolus, Inc. (NASDAQ:EOLS)Formula Growth Ltd. reduced its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 34.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 90,830 shares of the company's stock after selling 47,170 shaApril 21, 2025 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) Shares Bought by Altium Capital Management LLCAltium Capital Management LLC lifted its stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 93.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 685,000 shares of the company's stock after purchasing an additionApril 20, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Earns Buy Rating from Analysts at BTIG ResearchApril 20, 2025 | americanbankingnews.comEvolus (NASDAQ:EOLS) Shares Gap Up - Here's WhyEvolus (NASDAQ:EOLS) Shares Gap Up - Here's What HappenedApril 19, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Now Covered by Analysts at BTIG ResearchBTIG Research initiated coverage on shares of Evolus in a research report on Thursday. They issued a "buy" rating and a $21.00 price objective on the stock.April 19, 2025 | marketbeat.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 18, 2025 | businesswire.comBTIG Initiates Coverage of Evolus (EOLS) with Buy RecommendationApril 18, 2025 | msn.comEvolus initiated with a Buy at BTIGApril 17, 2025 | markets.businessinsider.comEvolus Announces Commercial Launch of Evolysse™April 17, 2025 | finance.yahoo.comEvolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid GelsApril 15, 2025 | finance.yahoo.comFY2025 Earnings Forecast for Evolus Issued By HC WainwrightEvolus, Inc. (NASDAQ:EOLS - Free Report) - Equities researchers at HC Wainwright decreased their FY2025 earnings estimates for Evolus in a research report issued to clients and investors on Thursday, April 10th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per shaApril 15, 2025 | marketbeat.comHC Wainwright Brokers Decrease Earnings Estimates for EvolusEvolus, Inc. (NASDAQ:EOLS - Free Report) - Research analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Evolus in a report issued on Thursday, April 10th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $0.41 for theApril 13, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $27.00 target price on shares of Evolus in a research report on Thursday.April 12, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Hits New 12-Month Low - Here's What HappenedEvolus (NASDAQ:EOLS) Hits New 52-Week Low - What's Next?April 11, 2025 | marketbeat.comBreaking Down Evolus: 8 Analysts Share Their ViewsApril 11, 2025 | nasdaq.comNeedham & Company LLC Reiterates "Buy" Rating for Evolus (NASDAQ:EOLS)Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Evolus in a research note on Wednesday.April 11, 2025 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) Stake Reduced by Trexquant Investment LPTrexquant Investment LP decreased its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 33.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 163,937 shares of the company's stock aApril 11, 2025 | marketbeat.comRaymond James Financial Inc. Takes $575,000 Position in Evolus, Inc. (NASDAQ:EOLS)Raymond James Financial Inc. acquired a new stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 52,035 shares of the compApril 9, 2025 | marketbeat.comSchroder Investment Management Group Raises Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)Schroder Investment Management Group raised its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 2.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,040,440 shares of the company's stock after buying an adApril 5, 2025 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) Insider David Moatazedi Sells 6,251 SharesEvolus, Inc. (NASDAQ:EOLS - Get Free Report) insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the completion of the sale, the insider now owns 508,619 shares of the company's stock, valued at approximately $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.March 29, 2025 | marketbeat.comEvolus to Participate in The Needham 24th Annual Virtual Healthcare ConferenceMarch 25, 2025 | finance.yahoo.comEvolus (NASDAQ:EOLS) Trading Down 2.4% - Should You Sell?Evolus (NASDAQ:EOLS) Stock Price Down 2.4% - What's Next?March 25, 2025 | marketbeat.comInvesting in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gainMarch 23, 2025 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) CMO Sells $60,147.36 in StockEvolus, Inc. (NASDAQ:EOLS - Get Free Report) CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $60,147.36. Following the completion of the transaction, the chief marketing officer now owns 95,671 shares of the company's stock, valued at approximately $1,268,597.46. This trade represents a 4.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.March 21, 2025 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver Sells 8,996 SharesEvolus, Inc. (NASDAQ:EOLS - Get Free Report) CFO Sandra Beaver sold 8,996 shares of the business's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $119,286.96. Following the completion of the transaction, the chief financial officer now owns 173,583 shares in the company, valued at $2,301,710.58. This represents a 4.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 21, 2025 | marketbeat.comRui Avelar Sells 27,904 Shares of Evolus, Inc. (NASDAQ:EOLS) StockEvolus, Inc. (NASDAQ:EOLS - Get Free Report) insider Rui Avelar sold 27,904 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the sale, the insider now owns 362,467 shares of the company's stock, valued at $4,806,312.42. This trade represents a 7.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.March 21, 2025 | marketbeat.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 | businesswire.comEvolus, Inc. (NASDAQ:EOLS) CMO Sells $60,147.36 in StockMarch 21, 2025 | insidertrades.comEvolus, Inc. (NASDAQ:EOLS) Director Sells $167,415.12 in StockEvolus, Inc. (NASDAQ:EOLS - Get Free Report) Director Karah Herdman Parschauer sold 12,888 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the completion of the sale, the director now owns 32,183 shares in the company, valued at approximately $418,057.17. This represents a 28.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 15, 2025 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) Director Karah Herdman Parschauer Sells 12,888 SharesMarch 15, 2025 | insidertrades.comBender Robert & Associates Invests $277,000 in Evolus, Inc. (NASDAQ:EOLS)Bender Robert & Associates purchased a new stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 25,070 shares of the company's stock, valued at approximately $277,00March 12, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Trading Down 9.6% - What's Next?Evolus (NASDAQ:EOLS) Shares Down 9.6% - Here's What HappenedMarch 11, 2025 | marketbeat.comEssex Investment Management Co. LLC Has $2.02 Million Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)Essex Investment Management Co. LLC decreased its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 38.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 182,503 shares of the company's stock after seMarch 10, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Evolus FY2025 Earnings?Evolus, Inc. (NASDAQ:EOLS - Free Report) - Research analysts at HC Wainwright decreased their FY2025 earnings per share estimates for shares of Evolus in a research note issued on Wednesday, March 5th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.23) per share for thMarch 10, 2025 | marketbeat.comEvolus' (EOLS) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Evolus in a report on Wednesday.March 6, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research note on Wednesday.March 6, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Price Target Raised to $25.00Barclays increased their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday.March 6, 2025 | marketbeat.comEvolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market UncertaintyMarch 6, 2025 | tipranks.comEvolus (NASDAQ:EOLS) Issues Earnings Results, Misses Estimates By $0.09 EPSEvolus (NASDAQ:EOLS - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.09). Evolus had a negative return on equity of 847.60% and a negative net margin of 22.33%.March 5, 2025 | marketbeat.comEvolus price target raised to $25 from $22 at BarclaysMarch 5, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE) and Evolus (EOLS)March 5, 2025 | markets.businessinsider.comEvolus, Inc. (EOLS) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | seekingalpha.comEvolus, Inc. 2024 Q4 - Results - Earnings Call PresentationMarch 4, 2025 | seekingalpha.comEvolus reports Q4 EPS (11c) vs (21c) last yearMarch 4, 2025 | markets.businessinsider.comEvolus sees FY25 revenue $345M-$355M, consensus $351.94MMarch 4, 2025 | markets.businessinsider.comEvolus posts quarterly profit on strong sales of cosmetic injectionMarch 4, 2025 | reuters.comEvolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 GuidanceMarch 4, 2025 | businesswire.com Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address EOLS Media Mentions By Week EOLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EOLS News Sentiment▼0.940.73▲Average Medical News Sentiment EOLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EOLS Articles This Week▼104▲EOLS Articles Average Week Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MoonLake Immunotherapeutics News Today Alvotech News Today Immunovant News Today HUTCHMED News Today ACADIA Pharmaceuticals News Today Apellis Pharmaceuticals News Today Amneal Pharmaceuticals News Today Recursion Pharmaceuticals News Today ImmunityBio News Today Biohaven News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EOLS) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EOLS Stock Free EOLS Stock Alerts